Critical Test Discontinued, Putting Rural Pregnant Women at Risk
A vital test used to detect signs of premature labour is being discontinued, raising concerns for pregnant women in rural and remote areas. The decision by the US-based manufacturer, Hologic, to cease production of the rapid foetal fibronectin (fFN) test has left healthcare providers worried about the potential impact on maternal and infant health, particularly in regions where medical resources are already stretched thin.
The Importance of the fFN Test
The fFN test has been a cornerstone in managing early labour risks, especially for women in rural and remote communities. This test helps doctors determine whether a woman is showing early signs of labour. The test involves taking a swab from the cervix and testing for traces of foetal fibronectin, which is a protein that is found between the amniotic sac and the uterus. A low reading indicates that labour is unlikely, while a high reading suggests that birth could occur within the week.
Impact on Rural Health Services
The discontinuation of the fFN test has sparked concern among healthcare providers in rural and remote regions. Without access to this test, doctors fear they will have to rely on less accurate methods, which could lead to unnecessary hospital transfers or missed signs of premature labour.
Dr Antoinette Mowbray, a GP in rural Victoria, expressed her frustration with the loss of the fFN test. “We are not happy having to take a backward step. We feel like it’s going to make working in rural areas harder,” she said. “You can go based on what your clinical judgement is but … sometimes your confidence level, based on the information that you have, can be quite variable.”
A Call for Action
Healthcare professionals are urging the Federal Government to intervene. Dr Mowbray and others argue that the long-term costs of unnecessary transfers and treating premature babies in rural settings could far exceed the expense of keeping the fFN test available and has suggested that state and territory governments could consider funding the test.
While alternative tests exist, they lack the reliability of the fFN test, leaving doctors to navigate these challenges with fewer resources and greater risks.
For now, the focus remains on advocating for solutions that protect the health and safety of pregnant women and their babies in all parts of Australia.
DISCLAIMER
This article reflects the current law at the time of publication. It is intended for informational purposes only and does not constitute legal advice. The actual decisions in each case are summarised for general understanding. For specific legal guidance in relation to your situation, please consult with a qualified legal professional.
